Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Bupranolol
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral, topical (eye drops)
ATC code
Pharmacokinetic data
Bioavailability< 10%
Protein binding76%
MetabolismFirst pass elimination > 90%
Elimination half-life2-4 hours (plasma)
Excretion> 88% renal (as carboxybupranolol)
Identifiers
  • (RS)-1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H22ClNO2
Molar mass271.79 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O
  • InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3 checkY
  • Key:HQIRNZOQPUAHHV-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Uses and dosage

edit

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia.[citation needed] The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.[citation needed]

Pharmacology

edit

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 μg/L in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.[citation needed]

Adverse effects, contraindications, interactions

edit

Adverse effects, contraindications and interactions are similar to other beta blockers.[citation needed]

References

edit

Further reading

edit
  • Dinnendahl V, Fricke U (2007). Arzneistoff-Profile (in German). Vol. 2 (21 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.